Latest Breaking News On - Biopharma mission - Page 2 : comparemela.com

Zydus Cadila on Thursday submitted data from phase one and two clinical trials for its coronavirus vaccine ZyCov-D and sought approval for the next phase of tests. The vaccine was found to be safe and well tolerated in tests on more than a thousand healthy adult volunteers, said the company, adding phase three clinical trial in around 30,000 volunteers upon receiving necessary approvals. The multi-centre and randomized trials were reviewed by an independent Data Safety Monitoring Board (DSMB). Reports have been submitted to Central Drugs Standard Control Organisation (CDSCO) regularly for the update on safety outcome. Zydus Group chairperson Pankaj Patel said that company is optimistic of the phase III clinical trial outcomes as well. We would be able to start production of the novel vaccine on its successful completion, he said.

Pankaj patelNational biopharma missionZydus groupCentral drugs standard control organisationDepartment of biotechnologyZydus cadilaData safety monitoring boardBiopharma missionCorona virusCoronavirus newsCoronavirus testsபங்கஜ் படேல்ஜய்துச் குழுமைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்துறை ஆஃப் உயிரி தொழில்நுட்பவியல்ஜய்துச் காடிலா